Fairvalue-Calculator Fairvalue-Calculator
EN DE

Health & Life Co (1781) Fair Value & Analysis

Healthcare · TW · Market cap 564M TWD

Price11.60 TWD
Fair Value20.29 TWD
Upside+74.9%
Quality95/100
Evidence: Low Range 15.21 TWD – 25.36 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Health & Life Co (1781) currently trades at 11.60 TWD, while our model-based Fair Value estimate is 20.29 TWD — implying the stock looks roughly 74.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Health & Life Co., Ltd. manufactures and sells products for cardiovascular disease, in-vitro diagnostics, and respiratory care worldwide. It offers vibrating mesh nebulizers, blood pressure monitor products, IR thermometers, and hearing aid devices. The company was founded in 1996 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Health & Life Co (1781) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 20.29 TWD versus a price of 11.60 TWD — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1781?
Our 21-model fair value for Health & Life Co is 20.29 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 11.60 TWD.
What is the quality score of 1781?
Health & Life Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.